Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
C-Rad AB has the GF Score of 91, which implies that the company
might have
Highest outperformance potential.
The GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation, which has been found to be closely correlated to the long-term performances of stocks by backtesting from 2006 to 2021. The stocks with a higher GF Score generally generate higher returns than those with lower GF Scores. Therefore, when picking stocks, investors should invest in companies with high GF Scores. The GF Score ranges from 0 to 100, with 100 as the highest rank.
GF Score takes following five key aspects into consideration:
Each one of these components is ranked and the ranks also have positive correlation with the long term performances of stocks. The GF score is calculated using the five key aspects of analysis. Through backtesting, we know that each of these key aspects has a different impact on the stock price performance. Thus, they are weighted differently when calculating the total score. The Profitability Rank and the Growth Rank are weighted fully, while other parameters have less weight.
Based on research and backtesting result, GuruFocus believes C-Rad AB
might have
Highest outperformance potential.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
C-Rad AB (FRA:24C) GF Score Explanation
Based on the historical long-term performances among five valuation aspects, the GF Score is found to be closely correlated to the long-term performances of stocks. It ranges from 0 to 100, with 100 as the highest. GuruFocus divided GF Score into following 5 categories:
GF Score
Performance Potential and All-in-One Screener Examples (1)
(1) These are some simple examples. You can access our GF Score filter under All-in-One Screener’s Fundamental tab.
C-Rad AB GF Score Related Terms
FRA:24C vs ABT, SYK, MDT: GF Score Comparison
For the Medical Devices subindustry, C-Rad AB's GF Score, along with its competitors' market caps and GF Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
C-Rad AB GF Score vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, C-Rad AB's GF Score distribution charts can be found below:
* The bar in red indicates where C-Rad AB's GF Score falls into.
C-Rad AB (FRA:24C) has a GF Score of 91 as of Jul. 29, 2026. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on C-Rad AB and its competitors. This is 11% above median its historical median of 82.00. Over the past decade, C-Rad AB's GF Score has ranged from 26.00 to 93.00.
Is C-Rad AB's GF Score too high?
C-Rad AB's current GF Score of 91 is 11% above median its 10-year median of 82.00. Over the past 10 years, this metric has ranged from a low of 26.00 to a high of 93.00. Overall, C-Rad AB has a GF Score™ of 91/100, reflecting its overall financial health beyond just this single metric.
How does C-Rad AB's GF Score compare to ABT and SYK?
C-Rad AB's GF Score of 91 can be compared against companies in the Medical Devices & Instruments industry. Historically, C-Rad AB's own GF Score has ranged from 26.00 to 93.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Score for a Medical Devices & Instruments company?
A good GF Score depends on the Medical Devices & Instruments industry context. However, GF Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Score mean?
A high GF Score can signal that a stock is expensive relative to its fundamentals. GF Score is a stock performance ranking system developed by GuruFocus using five aspects of valuation. View historical data on C-Rad AB and its competitors. C-Rad AB's current GF Score is 91, which is 11% above median its own 10-year median of 82.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is C-Rad AB stock overvalued right now?
C-Rad AB (FRA:24C) has a current GF Score of 91. The stock's GF Value™ is €2.86, compared to a current price of €3.20 — trading 11.9% above its estimated fair value. The current GF Score is 91, which is 11% above median its 10-year median of 82.00. C-Rad AB's overall GF Score™ is 91/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Score calculated?
GF Score is calculated from a company's financial statements. For C-Rad AB (FRA:24C), the current GF Score is 91 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is C-Rad AB (FRA:24C) Overvalued in 2026?
Based on GuruFocus' analysis, C-Rad AB stock appears to be overvalued.
The current stock price of €3.20 is trading 11.9% above its estimated GF Value™ of €2.86.
Key valuation signals for FRA:24C:
GF Score: 91 (11% above median its 10-year median of 82.00)
GF Value™: €2.86 vs. price of €3.20 (11.9% above fair value)
No single metric tells the full story. See the FRA:24C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
C-Rad AB is a Sweden-based company engaged in the development and sales of systems with applications in radiation therapy for the treatment of cancer. The systems can be used to position the patient before the treatment and to localize and monitor the tumor by recording information such as patient movements during radiation treatment. Its product portfolio includes the Catalyst and Sentinel systems. Geographically, the company generates a majority of its revenue from Asia Pacific region, and also has its presence in Europe, Middle East and Africa and the rest from Americas.
91GF Score
Get the complete analysis for FRA:24C
GF Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:24C has been successfully added to your 
